Daytrana

Methylphenidate transdermal patch — same drug as Ritalin, delivered through skin via a 9-hour wear-and-remove patch. FDA-approved 2006 for pediatric ADHD ages 6-17 (rare adult use). For Dylan: NOT-RELEVANT HIGH — patch adhesion fails under sweat and grappling skin contact, ~$400-600/month retail with no generic, and the 2015 FDA boxed-warning-adjacent label change for chemical leukoderma (permanent skin depigmentation) turns a stim-class drug into a cosmetic-injury risk for a 20yo athlete. Every feature Daytrana offers (flexible duration, swallowing avoidance) is either irrelevant to Dylan or already provided more cleanly by oral IR methylphenidate.

Drug: Daytrana contains the same racemic methylphenidate as Ritalin/Concerta. The dextro-threo enantiomer (d-MPH) does ~90% of the pharmacological work. Mechanism is identical: blocks the dopamine transporter (DAT) and norepinephrine transporter (NET), raising synaptic dopamine and norepinephrine in prefrontal cortex (focus, executive function) and dorsal striatum (motor/attention gating). Reuptake inhibition only — does NOT cause vesicular release like amphetamines.

Delivery — what makes Daytrana different:

Daytrana uses Noven's DOT Matrix transdermal patch technology — a thin, multilayer adhesive matrix (rather than a reservoir patch) where methylphenidate is dissolved directly into the adhesive polymer. As the patch sits on skin, drug partitions through the stratum corneum and into dermal capillaries continuously, with flux roughly proportional to the area of skin contact and duration of wear.

Patch sizes (and corresponding daily dose at 9-hour wear): 10 mg/9 hr (12.5 cm²), 15 mg/9 hr (18.75 cm²), 20 mg/9 hr (25 cm²), 30 mg/9 hr (37.5 cm²). Larger patches deliver more drug because more surface area is in contact with skin — there is no chemical difference between patches, only size.

Transdermal pharmacokinetics:

• First-pass bypass: Transdermal delivery skips hepatic first-pass metabolism, which means a given amount of methylphenidate that crosses skin yields higher systemic exposure of d-MPH (the active enantiomer) relative to l-MPH than oral dosing produces. Oral methylphenidate is heavily first-pass-metabolized; the l-isomer is preferentially cleared, leaving an oral d:l ratio ~6:1 in plasma. Transdermal Daytrana skips this enantio-selective metabolism, producing a d:l plasma ratio closer to ~1.5-2:1 — meaning more total l-MPH exposure at any d-MPH-equivalent dose. l-MPH is largely inactive at DAT/NET but contributes some peripheral sympathomimetic load (this is one mechanistic reason Daytrana isn't simply "Ritalin with a different route").
• Tmax (peak plasma): ~7-10 hours of patch wear. Plasma concentrations rise gradually for the first 2-4 hours (slow flux through stratum corneum), then plateau toward the end of wear time.
• Removable on-demand: Plasma concentrations decline within ~3 hours of patch removal due to the short half-life of methylphenidate (~3.5 hours, same as oral). This removability is Daytrana's defining feature — allows truncating duration for an early afternoon cutoff (e.g., apply at 7 AM, remove at noon for a 6-hour duration).
• Metabolism: Identical to oral methylphenidate — primarily by carboxylesterase 1 (CES1), NOT CYP-mediated. Major metabolite: ritalinic acid (inactive). CYP2D6 not involved.
• Application sites: Hip (alternate hips daily) is the FDA-recommended site. Avoid waistband areas, areas with heavy hair, irritated skin, or areas under clothing pressure points.

Why a patch at all? The clinical problem Daytrana solves is pediatric — kids who can't or won't swallow pills (Concerta is a large monolithic tablet), kids who "cheek" pills, kids whose ADHD symptoms vary across the school day in ways that benefit from on-demand duration adjustment, and kids with ADHD comorbid with eating disorders where appetite suppression timing matters. Adults rarely have these constraints.